Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:54 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
NCT00481832 · Stanford University · PHASE2 · terminated · last registry update 2018-02-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Accrual Factor” | – | Registry record, Stanford University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GSR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-12-28Results posted on the registry: Fred Hutchinson Cancer Center, Carmustine + Filgrastim (NCT00669669)
- 2018-11-20Also stopped (withdrawn): Fred Hutchinson Cancer Center, C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs + Carmustine (NCT02343666)
- 2018-11-20Results posted on the registry: Cedars-Sinai Medical Center, Temozolomide (NCT01235793)
- 2018-11-20Also stopped (terminated): Cedars-Sinai Medical Center, Temozolomide (NCT01235793)
- 2018-10-26Phase 3 first posted: Radiation Therapy Oncology Group, Carmustine (NCT03722355)
- 2018-09-04Results posted on the registry: Fred Hutchinson Cancer Center, Carmustine + Cytarabine (NCT01921387)
- 2018-07-26Results posted on the registry: University of Nebraska, Bortezomib + BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan) (NCT00571493)
- 2018-07-06Results posted on the registry: City of Hope Medical Center, rituximab + carmustine (NCT00695409)
- 2018-06-27Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, temozolomide (NCT00238277)
- 2018-05-16Also stopped (withdrawn): Beth Israel Deaconess Medical Center, trastuzumab + carboplatin (NCT00006123)
- 2018-05-14Results posted on the registry: Stanford University, Rituximab + Carmustine (NCT00482053)
- 2018-05-14Also stopped (terminated): Stanford University, Rituximab + Carmustine (NCT00482053)
- 2018-04-04Also stopped (terminated): Western Regional Medical Center, Dacarbazine + Carmustine (NCT01692691)
- 2018-03-12Also stopped (terminated): City of Hope Medical Center, Carmustine + Etoposide (NCT02366663)
- 2018-02-13Results posted on the registry: City of Hope Medical Center, Carmustine + Etoposide (NCT02366663)
- 2018-01-09Also stopped (withdrawn): University of California, Davis, Bevacizumab + Carmustine (NCT02348255)
- 2017-12-12Results posted on the registry: Stanford University, Cyclophosphamide + Etoposide (NCT00349778)
- 2017-12-07Results posted on the registry: Fred Hutchinson Cancer Center, Carmustine + Cyclophosphamide (NCT00005803)
- 2017-11-29Also stopped (terminated): Masonic Cancer Center, University of Minnesota, carmustine + cyclophosphamide (NCT00005987)
- 2017-11-29Also stopped (withdrawn): Masonic Cancer Center, University of Minnesota, carmustine + cyclophosphamide (NCT00005998)
- 2017-11-20Also stopped (terminated): University of Arkansas, Interim/Maintenance Dexamethasone + Induction/Consolidation Dexamethasone (NCT00574080)
- 2017-11-13Results posted on the registry: Radiation Therapy Oncology Group, BCNU 80mg/m2 + TMZ 200mg/m2 (NCT00004259)
- 2017-09-27Also stopped (terminated): OHSU Knight Cancer Institute, anti-thymocyte globulin + filgrastim (NCT00281879)
- 2017-08-14Results posted on the registry: University College, London, 5-ALA + Gliadel wafers (NCT01310868)
- 2017-06-28Results posted on the registry: Barbara Ann Karmanos Cancer Institute, rituximab + busulfan (NCT00691015)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision